Skip to Content
  • Previous Rank478
  • Revenues ($M)$32,639
  • Revenue Percent Change31.1%
  • Profits ($M)$18,108
  • Profits Percent Change49.6%
  • Assets ($M)$51,839
  • Employees8,000

The California-based biotech continued its rocket-like ascent in 2015–just two years ago it ranked No. 250 on the 500–due to booming sales of its breakthrough Hepatitis C medications. Those drugs–Sovaldi and Harvoni–which cost a fortune, but also cure a chronic, devastating disease, sparked a national debate on drug pricing. They also drove Gilead’s bottom and top lines in 2015–revenues and profits jumped 31% and 50%, respectively. John Milligan, Gilead’s new CEO faces rockier road in 2016: the competition is stiffer and IP challenges and pricing pressures loom.

Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access

Company Information

John F. Milligan
Health Care
HQ Location
Foster City, CA
Years on Global 500 List2

Gilead Sciences Rank History

Key Financials (last fiscal year)

($ Millions)% change
Revenues ($M)$32,63931.1%
Profits ($M)$18,10849.6%
Assets ($M)$51,839-
Total Stockholder Equity ($M)$18,534-

Profit Ratios

Profit as % of Revenues55.5%
Profits as % of Assets34.9%
Profits as % of Stockholder Equity97.7%